UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 608

Sortiert nach

The negative impact of HBV/HCV coinfection on cirrhosis and its consequences

Alimentary pharmacology & therapeutics, 2017-12, Vol.46 (11-12), p.1054-1060

2017

Volltextzugriff (PDF)

Les hépatopathies cholestastiques chroniques

La Revue de médecine interne (Paris), 2014-06, Vol.35 (JUN), p.A2-A5

BOURLIERE, M

2014

Volltextzugriff (PDF)

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

Clinical chemistry (Baltimore, Md.), 2007-09, Vol.53 (9), p.1615-1622

2007

Volltextzugriff (PDF)

The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non‐invasive fibrosis biomarkers: an international study of 2411 cases

Alimentary pharmacology & therapeutics, 2011-11, Vol.34 (10), p.1202-1216

2011

Volltextzugriff (PDF)

The accuracy of the FIB‐4 index for the diagnosis of mild fibrosis in chronic hepatitis B

Alimentary pharmacology & therapeutics, 2009-02, Vol.29 (4), p.409-415

2009

Volltextzugriff (PDF)

Hepatitis C therapy in non-genotype 1 patients: the near future

Journal of viral hepatitis, 2012-08, Vol.19 (8), p.525-536

2012

Volltextzugriff (PDF)

Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data

DIGESTIVE AND LIVER DISEASE, 2023-03, Vol.55, p.S74-S74

2023

Volltextzugriff (PDF)

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B

Gastroenterology (New York, N.Y. 1943), 2004-01, Vol.126 (1), p.91-101

2004

Volltextzugriff (PDF)

A national survey of acute hepatitis E in France

Alimentary pharmacology & therapeutics, 2008-06, Vol.27 (11), p.1086-1093

2008

Volltextzugriff (PDF)

Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation

Alimentary pharmacology & therapeutics, 2007-03, Vol.25 (6), p.733-739

2007

Volltextzugriff (PDF)

RNA editing blood biomarkers for predicting mood alterations in HCV patients

Journal of neurovirology, 2019-12, Vol.25 (6), p.825-836

2019

Volltextzugriff (PDF)

Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C

Alimentary pharmacology & therapeutics, 2012-01, Vol.35 (1), p.92-104

2012

Volltextzugriff (PDF)

P0856 : Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin (RBV) has mild impact on Health-Related Quality of Life (HRQoL) compared with placebo during 12-week treatment in treatment-experienced adults with chronic hepatitis C (CHC)

Journal of hepatology, 2015-04, Vol.62, p.S661-S661

2015

Volltextzugriff (PDF)

P.09.14: Magnitude of Liver Stiffness Regression after Achieving Sustained Virologic Response in Patients with Chronic Hepatitis C: A Meta-Analysis

Digestive and liver disease, 2017-03, Vol.49, p.e192-e193

2017

Volltextzugriff (PDF)

Les marqueurs sanguins non invasifs de fibrose hépatique au cours de l'infection chronique par le virus de l'hépatite C

La revue de medecine interne, 2006-10, Vol.27 (10), p.751-761

2006

Volltextzugriff (PDF)

Ponction de la surrénale droite sous échoendoscopie : mythe ou réalité ?

Acta endoscopica, 2010-12, Vol.40 (6), p.447-449

2010

Volltextzugriff (PDF)

Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma

Journal of hepatology, 2017, Vol.66 (1), p.S491-S492

2017

Volltextzugriff (PDF)

Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin

Journal of viral hepatitis, 2016-03, Vol.23 (3), p.227-231

2016

Volltextzugriff (PDF)

Impact of common risk factors of fibrosis progression in chronic hepatitis C

Gut, 2015-10, Vol.64 (10), p.1605-1615

2015

Volltextzugriff (PDF)

481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S197-S197

2011

Volltextzugriff (PDF)

High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4

Journal of hepatology, 2017, Vol.66 (1), p.S114-S114

2017

Volltextzugriff (PDF)

1366 HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S541-S542

2011

Volltextzugriff (PDF)

Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world

Journal of hepatology, 2017, Vol.66 (1), p.S730-S731

2017

Volltextzugriff (PDF)

Retreatment of hepatitis C virus daa failures in real life: easy and difficult to cure patients

Journal of hepatology, 2017, Vol.66 (1), p.S304-S304

2017

Volltextzugriff (PDF)

Traitement de l’hépatite C : gestion des effets secondaires

Gastroentérologie clinique et biologique, 2008-05, Vol.32 (5), p.S166-S171

Bourliere, M.

2008

Volltextzugriff (PDF)

1 – 25 von 608

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(426)
Mit Volltextzugriff
(514)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(233)
Science & Technology
(180)
Life Sciences & Biomedicine
(179)
Female
(151)
Male
(144)
Gastroenterology And Hepatology
(113)
Middle Aged
(106)
Gastroenterology & Hepatology
(98)
Adult
(96)
Biological And Medical Sciences
(66)
Medical Sciences
(66)
Infectious Diseases
(65)
Aged
(56)
Hepatitis C, Chronic - Drug Therapy
(55)
Hepatitis C Virus
(52)
Antiviral Agents - Therapeutic Use
(51)
Hepacivirus - Genetics
(47)
Genotype
(46)
Hepatitis C, Chronic - Virology
(45)
Life Sciences
(45)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

The negative impact of HBV/HCV coinfection on cirrhosis and its consequences

Les hépatopathies cholestastiques chroniques

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non‐invasive fibrosis biomarkers: an international study of 2411 cases

The accuracy of the FIB‐4 index for the diagnosis of mild fibrosis in chronic hepatitis B

Hepatitis C therapy in non-genotype 1 patients: the near future

Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B

A national survey of acute hepatitis E in France

Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation

RNA editing blood biomarkers for predicting mood alterations in HCV patients

Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C

P0856 : Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin (RBV) has mild impact on Health-Related Quality of Life (HRQoL) compared with placebo during 12-week treatment in treatment-experienced adults with chronic hepatitis C (CHC)

P.09.14: Magnitude of Liver Stiffness Regression after Achieving Sustained Virologic Response in Patients with Chronic Hepatitis C: A Meta-Analysis

Les marqueurs sanguins non invasifs de fibrose hépatique au cours de l'infection chronique par le virus de l'hépatite C

Ponction de la surrénale droite sous échoendoscopie : mythe ou réalité ?

Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma

Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin

Impact of common risk factors of fibrosis progression in chronic hepatitis C

481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4

1366 HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN

Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world

Retreatment of hepatitis C virus daa failures in real life: easy and difficult to cure patients

Traitement de l’hépatite C : gestion des effets secondaires

Suchergebnisse filtern